THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [3.34] ID: TIP-MED-000034

Clonidine Hydrochloride

Active Ingredient / Scientific Identity: Clonidine Hydrochloride • Class: Central Alpha-2 Adrenoceptor & Imidazoline Receptor Agonist (Schedule H)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Clonidine Hydrochloride ([3.34] | ID: TIP-MED-000034) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/3-34-clonidine-hydrochloride/
Generic / Entity NameClonidine Hydrochloride ([3.34])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassCentral Alpha-2 Adrenoceptor & Imidazoline Receptor Agonist (Schedule H)
Available Dosage FormsTablets: 100 mcg (0.1 mg); Injection: 150 mcg/mL
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: 50% renally excreted — start at 50–100 mcg BD in Stage 4–5 CKD/dialysis (no supplemental post-HD dose needed). Hepatic
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Clonidine Hydrochloride (TIP-MED-000034, Reference Code [3.34]) is classified under Cardiovascular & Antithrombotic Medicines (Ch 03) as a Central Alpha-2 Adrenoceptor & Imidazoline Receptor Agonist (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.34], p. 37): Arkamin (Unichem), Catapres (Boehringer), Cloneon (Neon) — Strengths & Dosage Forms: Tablets: 100 mcg (0.1 mg); Injection: 150 mcg/mL
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.34], p. 37): Arkamin (Unichem), Catapres (Boehringer), Cloneon (Neon) — Strengths & Dosage Forms: Tablets: 100 mcg (0.1 mg); Injection: 150 mcg/mL
Dosage Forms & Available Strengths:
Tablets: 100 mcg (0.1 mg); Injection: 150 mcg/mL
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Central Alpha-2 Adrenoceptor & Imidazoline Receptor Agonist (Schedule H) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Central Alpha-2 Adrenoceptor & Imidazoline Receptor Agonist (Schedule H) for Resistant hypertension (especially in advanced CKD/dialysis when 3–4 agents fail), hypertensive urgency, opioid/alcohol withdrawal symptom adjunct.

4. Therapeutic Indications & Evidence-Supported Uses

  • Resistant hypertension (especially in advanced CKD/dialysis when 3–4 agents fail), hypertensive urgency, opioid/alcohol withdrawal symptom adjunct

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Start 50–100 mcg (0.5–1 tablet) PO BD–TDS; titrate gradually to 100–200 mcg TDS (Max 600–900 mcg/day)

Administration & Meal Timing: May be taken with or without food; take largest fraction at bedtime to minimise daytime sedation | Morning, Afternoon & Bedtime (TDS — short 8–12h duration requires strict 8-hourly adherence!)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: 50% renally excreted — start at 50–100 mcg BD in Stage 4–5 CKD/dialysis (no supplemental post-HD dose needed). Hepatic: Caution
Elimination & Renal Adjustment:
Renal: 50% renally excreted — start at 50–100 mcg BD in Stage 4–5 CKD/dialysis (no supplemental post-HD dose needed). Hepatic: Caution
Hepatic Impairment Considerations:
Renal: 50% renally excreted — start at 50–100 mcg BD in Stage 4–5 CKD/dialysis (no supplemental post-HD dose needed). Hepatic: Caution

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • SEVERE REBOUND HYPERTENSIVE CRISIS: Abrupt discontinuation causes life-threatening sympathetic catecholamine surge, encephalopathy, and stroke! Never stop Clonidine while a patient is also on a non-selective Beta-Blocker (stop beta-blocker several days BEFORE tapering Clonidine!)

Key Clinical Precautions: Renal: 50% renally excreted — start at 50–100 mcg BD in Stage 4–5 CKD/dialysis (no supplemental post-HD dose needed). Hepatic: Caution

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Marked dry mouth (xerostomia — 40%), drowsiness/sedation, dizziness, constipation, bradycardia
  • Life-threatening rebound hypertensive crisis on missed/stopped doses, severe sinus bradycardia, AV block, depression/delirium in elderly
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Tricyclic antidepressants (Amitriptyline, Nortriptyline) and Mirtazapine ANTAGONISE Clonidine's antihypertensive effect and can precipitate hypertensive crisis! Additive sedation with CNS depressants; additive bradycardia with Beta-blockers/Digoxin

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: CRITICAL WARNING: Never stop Arkamin suddenly or allow your strip to run out — abrupt stopping causes dangerous blood pressure spikes; sip water or chew sugarless gum for dry mouth
  • Meal & Clock Timing Instruction: May be taken with or without food; take largest fraction at bedtime to minimise daytime sedation (Morning, Afternoon & Bedtime (TDS — short 8–12h duration requires strict 8-hourly adherence!))
  • Missed Dose Protocol: Take IMMEDIATELY as soon as remembered! Missing 2 consecutive doses can trigger rebound BP crisis
  • Geriatric Dispensing Pearl: Avoid as first-line antihypertensive in older adults (AGS Beers 2023: high CNS sedation, bradycardia, and orthostatic risk)

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablets: 100 mcg (0.1 mg); Injection: 150 mcg/mL

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.34] (p. 37)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/3-34-clonidine-hydrochloride/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.